Skip to main content
    I

    Immunovant Inc (IMVT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.28
    -0.90 (-2.63%)

    Market Cap: $7.07B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Immunovant Inc (IMVT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Immunovant reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was -$505.61M, operating cash flow was -$407.31M and free cash flow was -$407.32M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$97.25M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $532.90M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 2026$0N/AN/AN/AN/A
    Mar 2025$0N/AN/AN/AN/A
    Mar 2024$0N/AN/AN/AN/A
    Mar 2023$0N/AN/AN/AN/A
    Mar 2022$0N/AN/AN/AN/A
    Mar 2021$0N/AN/AN/AN/A
    Mar 2020$0N/AN/AN/AN/A
    Mar 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Mar 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Mar 2018 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Dec 2018Mar 2018
    Cost of revenue$409.00K$377.00K$231.00K$1.32M$1.23M$998.00K$21.00KN/AN/AN/A
    Gross profit-$409.00K-$377.00K-$231.00K-$1.32M-$1.23M-$998.00K-$21.00KN/AN/AN/A
    Research and development$456.66M$360.92M$212.93M$160.26M$101.81M$68.60M$47.93M$25.73M$0$135.26M
    Operating income-$532.90M-$438.15M-$270.21M-$208.28M-$156.03M-$108.12M-$59.68M-$450-$450-$136.74M
    Net income-$505.61M-$413.84M-$259.34M-$210.96M-$156.73M-$107.43M-$66.39M-$450-$450-$136.74M
    EBITDA-$504.98M-$412.57M-$258.54M-$198.28MN/A-$108.05MN/AN/AN/AN/A
    Fiscal years ended Mar 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$7.09M$0$0$0$0$160.00K$0$0$0$1.50M$0
    Gross profitN/A$7.09MN/A-$101.00K-$105.00K-$107.00K$80.00K-$99.00K-$89.00K-$80.00K$1.44M-$58.00K
    Operating income-$104.16M-$153.23M-$159.55M-$114.36M-$131.76M-$127.22M-$113.83M-$114.30M-$115.74M-$94.28M-$80.88M-$61.55M
    Net income-$97.25M-$153.22M-$147.86M-$110.64M-$126.50M-$120.61M-$106.45M-$111.12M-$109.12M-$87.15M-$75.32M-$51.42M
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, cash and equivalents exceeded short-term debt of $72.00K by $902.04M.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018
    Total assets$957.01M$776.22M$666.71M$405.84M$515.56M$412.49M$109.39M$405.00K$113.17K
    Current assets$948.82M$767.66M$665.77M$404.33M$512.93M$409.01M$109.08M$325.00K$113.17K
    Cash and equivalents$902.11M$713.97M$635.37M$376.53M$493.82M$400.15M$100.57M$325.00KN/A
    Total liabilities$104.42M$68.78M$48.95M$43.34M$45.74M$21.01M$15.32M$380.45K$1.61M
    Short-term debt$72.00K$98.00K$138.00K$1.17M$1.15M$1.18M$3.19M$300.00KN/A
    Shareholder equity$852.59M$707.45M$617.76M$362.49M$469.82M$391.48M$94.07M$24.55K-$1.50M
    Fiscal years ended Mar 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$760.97M$852.49M$957.01M$1.05B$582.96M$661.44M$776.22M$420.93M$515.71M$589.68M$666.71M$711.45M
    Total liabilities$104.02M$117.10M$104.42M$66.26M$63.25M$52.90M$68.78M$68.31M$66.65M$45.02M$48.95M$32.10M
    Cash and equivalents$722.27M$797.80M$902.11M$994.52M$521.87M$598.91M$713.97M$374.69M$472.94M$560.00M$635.37M$690.94M
    Shareholder equity$656.95M$735.39M$852.59M$986.13M$519.71M$608.54M$707.45M$352.62M$449.05M$544.66M$617.76M$679.34M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Mar 2026.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Dec 2018Mar 2018
    Operating cash flow-$407.31M-$375.87M-$214.23M-$188.19M-$106.11M-$83.33M-$53.36M-$28.55MN/A-$128.30M
    Capital expenditures$8.00K$759.00K$360.00K$197.00K$254.00K$210.00K$31.00K$52.00K$0$52.00K
    Free cash flow-$407.32M-$376.63M-$214.59M-$188.39M-$106.37M-$83.54M-$53.39M-$28.60MN/A-$128.35M
    Investing cash flow-$8.00K-$759.00K-$360.00K-$197.00K-$254.00K-$210.00K-$31.00K-$52.00KN/A-$52.00K
    Financing cash flow$595.76M$454.49M$472.43M$70.89M$200.13M$383.11M$146.97M$35.58M$325.00K$128.30M
    Fiscal years ended Mar 2018 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$83.22M-$124.41M-$95.06M-$92.33M-$102.52M-$117.41M-$110.64M-$100.39M-$88.65M-$76.20M-$59.70M-$47.10M
    Capital expenditures$0$0$8.00K$0$0$0$201.00K$180.00K$196.00K$182.00K$150.00K$131.00K
    Free cash flow-$83.22M-$124.41M-$95.07M-$92.33M-$102.52M-$117.41M-$110.84M-$100.57M-$88.84M-$76.38M-$59.85M-$47.23M
    Last 12 quarters

    Frequently Asked Questions About IMVT

    What is Immunovant's annual revenue?

    Immunovant reported revenue of $0 for the fiscal year ended Mar 31, 2026.

    Is Immunovant profitable?

    No. Immunovant reported net income of -$505.61M for the fiscal year ended Mar 31, 2026.

    How much free cash flow does IMVT generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of -$407.31M minus capital expenditures of $8.00K produced free cash flow of -$407.32M.

    How much debt does Immunovant have?

    The balance sheet dated Mar 31, 2026 reported short-term debt of $72.00K and cash and equivalents of $902.11M.